Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial
Verma S, Dhingra NK, Butler J, et al.
Lancet Diabetes Endocrinol. 2022;10(1):35-45.
Leggi